Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Efonidipine
- Development stage
- Unknown
- Lead developer
- Shionogi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Efonidipine is a dihydropyridine calcium channel blocker used primarily for the treatment of hypertension and angina. It blocks both L-type and T-type calcium channels, leading to vasodilation and decreased heart rate. This action results in reduced blood pressure and myocardial oxygen demand, while increasing coronary blood flow. Efonidipine also enhances renal function by increasing glomerular filtration rate without raising intra-glomerular pressure.
- Brand names
- LandelEfnocarFinte
- Other names
- EfonidipinoEfonidipine hydrochloriderac-Efonidipine
02
Targets
CaV3 (Caveolin-3)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on Efonidipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Efonidipine.